Cheng, Youshu
Dao, Cecilia
Zhou, Hang http://orcid.org/0000-0002-7694-6391
Li, Boyang
Kember, Rachel L. http://orcid.org/0000-0001-8820-2659
Toikumo, Sylvanus
Zhao, Hongyu http://orcid.org/0000-0003-1195-9607
Gelernter, Joel http://orcid.org/0000-0002-4067-1859
Kranzler, Henry R. http://orcid.org/0000-0002-1018-0450
Justice, Amy C.
Funding for this research was provided by:
U.S. Department of Veterans Affairs (I01 BX004820, I01 BX004820, I01 BX004820, I01 BX004820, I01 BX004820, I01 BX004820, I01 BX004820, I01 BX004820, I01 BX004820, I01 BX004820)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (R01 DA038632, R01 DA047063, R01 DA047820, R01 DA038632, R01 DA047063, R01 DA047820)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse
Article History
Received: 3 March 2023
Revised: 20 March 2023
Accepted: 22 March 2023
First Online: 5 May 2023
Competing interests
: HRK is a member of advisory boards for Dicerna Pharmaceuticals, Sophrosyne Pharmaceuticals, and Enthion Pharmaceuticals; a consultant to Sobrera Pharmaceuticals; the recipient of research funding and medication supplies for an investigator-initiated study from Alkermes; a member of the American Society of Clinical Psychopharmacology’s Alcohol Clinical Trials Initiative, which was supported in the last three years by Alkermes, Dicerna, Ethypharm, Lundbeck, Mitsubishi, and Otsuka; and a holder of U.S. patent 10,900,082 titled: “Genotype-guided dosing of opioid agonists,” issued 26 January 2021. The other authors have no competing interests to declare.